Can We Better Understand, Diagnose, and Treat Ketamine‐Induced Uropathy, and Can It Be Reversed? ICI‐RS 2024
Neurourology and Urodynamics · 2025
DOI: 10.1002/nau.25612 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, 2025. Verfasst von François Hervé und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, ERN Accredited Centrum, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Ketamine, Lower Urinary Tract Symptoms, Urologic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
Ketamine, a versatile anesthetic, has seen increased recreational use, leading to significant health issues, including ketamine‐induced uropathy (KIU). KIU manifests with lower urinary tract symptoms (LUTS) and can involve the upper urinary tract. This study aims to provide a comprehensive overview of KIU, addressing its pathophysiology, diagnostic strategies, and treatment options; and to define/identify future research priorities.
Methods
During the 2024 meeting of the International Consultation on Incontinence Research Society (ICI‐RS) in Bristol, a dedicated Proposal (P) convened to explore KIU. This initiative involved a thorough review of existing literature, expert presentations, and consensus‐driven discussions. The methodology ensured a comprehensive exploration of KIU from both clinical and pre‐clinical perspectives, leading to actionable research recommendations.
Results
Understanding the mechanisms of KIU is crucial for developing effective treatment options targeting specific pathophysiological pathways. Key findings include bladder fibrosis driven by transforming growth factor‐β1 (TGF‐β1), elevated purinergic responses and upregulated P2X1 purinoceptor expression, decreased barrier function due to increased expression of antiproliferative factor (APF), and functional loss of the bladder through Cav1.2 channel blockade. Research indicates that fibrosis, typically considered irreversible, may be mitigated. However, the exact timing and extent of fibrosis initiation and its impact on long‐term outcomes require further research. LUTS typically improve after ketamine cessation but relapse upon resumption, indicating a hypersensitivity mechanism involving elevated serum IgE levels. Advanced stages of KIU do not always correlate with LUTS severity, shedding light on potential systemic effects and the need for evaluating liver enzymes. Furthermore, psychological dependency on ketamine, due to its positive perceptive and mood‐altering effects, complicates cessation efforts. Long‐term management requires a holistic approach, integrating medical treatments and supportive measures to help patients navigate life with potentially irreversible complications.
Conclusion
This comprehensive review spans from fundamental pathology to practical clinical management, addressing both urological and systemic complications, and bridging insights from animal models to human applications. Developing effective treatment strategies necessitates addressing both the physical and psychological aspects of ketamine dependency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, ERN Accredited Centrum, Ghent University Hospital, Ghent, Belgium.
- Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Bristol Urological Institute, Southmead Hospital, Bristol, UK.
- Department of Urology, Research Institute for Mental Health and Neuroscience, Maastricht University and Maastricht University Medical Center+ (MUMC+), Maastricht, The Netherlands.
- Division of Neuro-Urology, Bambino Gesù Children Hospital and Research Institute, Rome, Italy.
- Department of Urology, Moinhos de Vento Hospital, Sao Lucas Hospital, PUCRS, Porto Alegre, Brazil.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Hervé, F., Aronsson, P., Ochoa, D. C., Van Koeveringe, G., Mosiello, G., Averbeck, M. A., Bou Kheir, G., Wyndaele, M., & Abrams, P. (2025). Can We Better Understand, Diagnose, and Treat Ketamine‐Induced Uropathy, and Can It Be Reversed? ICI‐RS 2024. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25612
Vancouver
Hervé F, Aronsson P, Ochoa DC, Van Koeveringe G, Mosiello G, Averbeck MA, et al. Can We Better Understand, Diagnose, and Treat Ketamine‐Induced Uropathy, and Can It Be Reversed? ICI‐RS 2024. Neurourology and Urodynamics. 2025. doi:10.1002/nau.25612
BibTeX
@article{Herv2025,
author = {Hervé, François and Aronsson, Patrik and Ochoa, D Carolina and Van Koeveringe, Gommert and Mosiello, Giovanni and Averbeck, Marcio Augusto and Bou Kheir, George and Wyndaele, Michel and Abrams, Paul},
title = {Can We Better Understand, Diagnose, and Treat Ketamine‐Induced Uropathy, and Can It Be Reversed? ICI‐RS 2024},
journal = {Neurourology and Urodynamics},
year = {2025},
doi = {10.1002/nau.25612}
}
EUVIMED